Al-Aqar Healthcare REIT (XKLS:5116) Research & Development: RM0.0 Mil (TTM As of Mar. 2026)


XKLS:5116 Al-Aqar Healthcare REIT XKLS:5116
70 GF Score
Price RM1.18
GF Value RM1.31
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Al-Aqar Healthcare REIT Research & Development?

Al-Aqar Healthcare REIT XKLS:5116 70 Research & Development is RM0.0 Mil as of Mar. 2026. GuruFocus rates XKLS:5116 with a GF Score™ of 70/100 and a GF Value™ of RM1.31 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Al-Aqar Healthcare REIT's Research & Development for the three months ended in Mar. 2026 was RM0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was RM0.0 Mil.

Al-Aqar Healthcare REIT  (XKLS:5116) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Al-Aqar Healthcare REIT Research & Development Related Terms

Al-Aqar Healthcare REIT Research & Development Historical Data

* Premium members only.

The historical data trend for Al-Aqar Healthcare REIT's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Al-Aqar Healthcare REIT Research & Development Chart

Al-Aqar Healthcare REIT Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Al-Aqar Healthcare REIT Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XKLS:5116
70GF Score
Al-Aqar Healthcare REIT XKLS:5116
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Al-Aqar Healthcare REIT Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of RM0.0 Mil mean?
Al-Aqar Healthcare REIT (XKLS:5116) has a Research & Development of RM0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Al-Aqar Healthcare REIT and its competitors.
Is Al-Aqar Healthcare REIT's Research & Development too high?
Al-Aqar Healthcare REIT's current Research & Development is RM0.0 Mil. Overall, Al-Aqar Healthcare REIT has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Al-Aqar Healthcare REIT's Research & Development compare to WELL and VTR?
Al-Aqar Healthcare REIT's Research & Development of RM0.0 Mil can be compared against companies in the REITs industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a REITs company?
A good Research & Development depends on the REITs industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Al-Aqar Healthcare REIT and its competitors. Al-Aqar Healthcare REIT's current Research & Development is RM0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Al-Aqar Healthcare REIT stock overvalued right now?
Based on GuruFocus' analysis, Al-Aqar Healthcare REIT (XKLS:5116) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.31, compared to a current price of RM1.18 — trading 9.9% below its estimated fair value. The current Research & Development is RM0.0 Mil. Al-Aqar Healthcare REIT's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Al-Aqar Healthcare REIT (XKLS:5116), the current Research & Development is RM0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Al-Aqar Healthcare REIT (XKLS:5116) Overvalued in 2026?

Based on GuruFocus' analysis, Al-Aqar Healthcare REIT stock appears to be undervalued. The current stock price of RM1.18 is trading 9.9% below its estimated GF Value™ of RM1.31. GuruFocus considers Al-Aqar Healthcare REIT to be Modestly Undervalued.

Key valuation signals for XKLS:5116:

  • Research & Development: RM0.0 Mil
  • GF Value™: RM1.31 vs. price of RM1.18 (9.9% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the XKLS:5116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Al-Aqar Healthcare REIT Business Description

Industry Real EstateREITs
Address Unit 1-19-02, Level 19, Block 1, V SQUARE, Jalan Utara, Petaling Jaya, SGR, MYS, 46200
Al-Aqar Healthcare REIT is engaged in investing in Syariah-compliant properties with the primary objective of providing unitholders with distribution and potential for the sustainable long-term growth of such distribution and capital appreciation. The company operates in Malaysia and Australia. The Malaysian geographic segment generates the maximum revenue for the company.
70GF Score

Get the complete analysis for XKLS:5116

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.18
Price
RM1.31
GF Value